Teijin Pharma widens Febuxostat business
The company has signed a deal with Menarini for Turkey market, which has been already marketing TMX-67 under the brand name Adenuric in Europe since March 2010 under
South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.